Bluebird Bio bought, relaunched as Genetix, now profitable

David Meek bought distressed gene therapy company Bluebird Bio, turned it into Genetix, and claims the rebranded company is already making money. This signals a potential resurgence for a biotech player previously struggling with commercialization bottlenecks. It's a look at how a change in leadership and strategy can revive a company even in complex fields like gene therapy.